FAMAR Group, a European pharmaceutical CDMO, has signed an agreement to acquire a sterile production site in Homburg, Germany, from MiP Pharma.

The acquisition represents a strategic milestone in FAMAR’s growth journey, strengthening its footprint in high-value dosage forms and expanding its capabilities in aseptic and lyophilized fill & finish.

The Homburg facility, which has recently undergone significant investment and modernization, will become an integral part of FAMAR’s international manufacturing network. When the transaction closes, FAMAR will operate 7 facilities across Europe, enhancing its ability to serve its customers with flexible, high-quality, and scalable production solutions.

“The Homburg site offers world-class sterile infrastructure, newly installed QC and microbiology laboratories, and a skilled workforce,” said Konstantinos Rengis, CEO of FAMAR Group. “This investment aligns with our strategy to grow in differentiated dosage forms and expand our capacity to support global customers with manufacturing services of the highest standards. We are proud to welcome the Homburg team to the FAMAR family and look forward to building a strong future together.”

As part of the transaction, approximately 100 employees will transfer to FAMAR, ensuring continuity and knowledge retention. The site will be developed into a multi-customer CDMO platform under FAMAR ownership, fully aligned with the company’s ambition to lead in complex and high-value pharmaceutical manufacturing.